PiggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies

126Citations
Citations of this article
150Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Nonviral integrating vectors can be used for expression of therapeutic genes. piggyBac (PB), a transposon/transposase system, has been used to efficiently generate induced pluripotent stems cells from somatic cells, without genetic alteration. In this paper, we apply PB transposition to express a chimeric antigen receptor (CAR) in primary human T cells. We demonstrate that T cells electroporated to introduce the PB transposon and transposase stably express CD19-specific CAR and when cultured on CD19+ artificial antigen-presenting cells, numerically expand in a CAR-dependent manner, display a phenotype associated with both memory and effector T cell populations, and exhibit CD19-dependent killing of tumor targets. Integration of the PB transposon expressing CAR was not associated with genotoxicity, based on chromosome analysis. PB transposition for generating human T cells with redirected specificity to a desired target such as CD19 is a new genetic approach with therapeutic implications. © 2010, Mary Ann Liebert, Inc. 2010.

Cite

CITATION STYLE

APA

Manuri, P. V. R., Wilson, M. H., Maiti, S. N., Mi, T., Singh, H., Olivares, S., … Cooper, L. J. N. (2010). PiggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Human Gene Therapy, 21(4), 427–437. https://doi.org/10.1089/hum.2009.114

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free